Summit Therapeutics
SMMT
105 hedge funds and large institutions have $205M invested in Summit Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.
334% more call options, than puts
Call options by funds: $915K | Put options by funds: $211K
138% more capital invested
Capital invested by funds: $86.3M → $205M (+$119M)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
8% more funds holding
Funds holding: 97 → 105 (+8)
2.35% more ownership
Funds ownership: 4.72% → 7.06% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$22.5M |
| 3 |
Rafferty Asset Management
New York
|
+$2.58M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.24M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.85M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$778K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$525K |
| 4 |
SPS
Susquehanna Portfolio Strategies
Bala Cynwyd,
Pennsylvania
|
-$502K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$444K |
SMMT Hedge Fund Activity: Q1 2024 in Review
105 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2024, worth a combined $205M — up 138% from $86.3M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SMMT positions and 11 closed out — a net gain of 8 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31.7M. The largest seller was Morgan Stanley, cutting an estimated $2.85M.
- 105 institutional investors held Summit Therapeutics (SMMT) as of Q1 2024, up from 97 in Q4 2023.
- Funds reported $205M of Summit Therapeutics stock for Q1 2024, up 138% quarter-over-quarter.
- 19 funds opened new Summit Therapeutics positions in Q1 2024 and 11 closed out, a net change of +8 holders.
- The largest Summit Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $31.7M added.
- The largest Summit Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $2.85M sold.
Based on aggregated 13F filings for Q1 2024.